human-immunodeficiency-virus

Documents about human-immunodeficiency-virus

• Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections#910955ClinicalTrials.gov
• Maternal mental health and caregiver competence of HIV-positive and negative women caring for their singleton newborns in KwaZulu-Natal Province, South Africa#197765University of Pretoria Repository
• The anatomical basis and rational for the transoral approach during the surgical excision of the sublingual salivary gland for the management of plunging ranula#197793University of Pretoria Repository
• An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)#904840ClinicalTrials.gov
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy#253159ClinicalTrials.gov
• Barriers to access and use of sexual reproductive health and human immunodeficiency virus services among adolescent girls and young women in Maputo City, Mozambique#306919African Journals Online
• Explainable AI-driven comparative analysis of machine learning models for predicting HIV viral nonsuppression in Ugandan patients : retrospective cross-sectional study#425973University of Pretoria Repository
• A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir#882701ClinicalTrials.gov
• The OPENS Trial: Offering Women PrEP (Aim 1)#913301ClinicalTrials.gov
• Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)#872401ClinicalTrials.gov
• Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus#619951eScholarship
• Evaluation of Problem Management Plus in Pregnant Women With HIV in Kenya#867891ClinicalTrials.gov
• Gender identity and HIV risk among men who have sex with men in Cape Town, South Africa#355835University of Pretoria Repository
• Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants#888129ClinicalTrials.gov
• A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)#180206ClinicalTrials.gov
• Infrastructural and human-resource factors associated with return of infant HIV test results to caregivers: secondary analysis of a nationally representative situational assessment, South Africa, 2010#372701University of Pretoria Repository
• KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)#900595ClinicalTrials.gov
• The Impact of Number of Medications on Falls in Aging Persons with Human Immunodeficiency Virus#492082eScholarship
• ComBaCaL HIV Prevention TwiCs#804089ClinicalTrials.gov
• A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59#868823ClinicalTrials.gov
• HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection#879866ClinicalTrials.gov